Literature DB >> 17237291

The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein.

Stephanie Brändlein1, Nicole Rauschert, Leo Rasche, Angela Dreykluft, Frank Hensel, Ernst Conzelmann, Hans-Konrad Müller-Hermelink, H Peter Vollmers.   

Abstract

Lipids are essential for normal and malignant cells during growth and differentiation. The turnover is strictly regulated because an uncontrolled uptake and accumulation is cytotoxic and can lead to lipoapoptosis: lipoptosis. The human monoclonal antibody SAM-6 binds to a cell surface receptor on malignant cells and to oxidized low-density lipoprotein (LDL). SAM-6 induces an excess of intracellular lipids, by overfeeding malignant cells with oxidized LDL, via a receptor-mediated endocytosis. The treated cells overaccumulate depots of cholesteryl esters and triglycerides. This lipid overaccumulation is tumor specific; nonmalignant cells neither bind the antibody nor harvest lipids after incubation. Because for both forms of apoptosis, the death domain dependent ("extrinsic") and independent ("intrinsic"), the activation of proteases is crucial, we also investigated this pathway in more detail. It was found that shortly after internalization of antibody/oxidized LDL/receptor complex and formation of lipid depots, cytochrome c is released by mitochondria. Followed by this, initiator caspase-8 and caspase-9 and effector caspase-3 and caspase-6 are activated. The mechanism of mitochondrial trigger (e.g., by free fatty acids) is under investigation. However, the present data indicate that the SAM-6 antibody induces an intrinsic-like form of apoptosis by overfeeding malignant cells with lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237291     DOI: 10.1158/1535-7163.MCT-06-0399

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  21 in total

Review 1.  Natural IgM in immune equilibrium and harnessing their therapeutic potential.

Authors:  Srini V Kaveri; Gregg J Silverman; Jagadeesh Bayry
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

Review 2.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

3.  GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.

Authors:  Leo Rasche; Johannes Duell; Inês C Castro; Valentina Dubljevic; Manik Chatterjee; Stefan Knop; Frank Hensel; Andreas Rosenwald; Hermann Einsele; Max S Topp; Stephanie Brändlein
Journal:  Haematologica       Date:  2015-01-30       Impact factor: 9.941

4.  Liquid formulations for stabilizing IgMs during physical stress and long-term storage.

Authors:  Monika Mueller; Maybelle Q T Loh; Rupert Tscheliessnig; Doris H Y Tee; Eddy Tan; Muriel Bardor; Alois Jungbauer
Journal:  Pharm Res       Date:  2012-11-10       Impact factor: 4.200

Review 5.  Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Authors:  Jens O Watzlawik; Bharath Wootla; Meghan M Painter; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Rev Neurother       Date:  2013-09       Impact factor: 4.618

Review 6.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

7.  High level expression of functional human IgMs in human PER.C6 cells.

Authors:  Anna Tchoudakova; Frank Hensel; Alec Murillo; Bernie Eng; Marketa Foley; Lakee Smith; Frank Schoenen; Antonia Hildebrand; Arndt-René Kelter; Leodevico L Ilag; H Peter Vollmers; Stephanie Brandlein; Jane McIninch; John Chon; Gene Lee; Marco Cacciuttolo
Journal:  MAbs       Date:  2009-03-24       Impact factor: 5.857

8.  Expression and glycoengineering of functionally active heteromultimeric IgM in plants.

Authors:  Andreas Loos; Clemens Gruber; Friedrich Altmann; Ulrich Mehofer; Frank Hensel; Melanie Grandits; Chris Oostenbrink; Gerhard Stadlmayr; Paul G Furtmüller; Herta Steinkellner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-31       Impact factor: 11.205

9.  The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the unfolded protein response regulator GRP78.

Authors:  Zachary Rosenes; Terrence D Mulhern; Danny M Hatters; Leodevico L Ilag; Barbara E Power; Chris Hosking; Frank Hensel; Geoffrey J Howlett; Yee-Foong Mok
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 10.  Humoral innate immune response and disease.

Authors:  Stephanie N Shishido; Sriram Varahan; Kai Yuan; Xiangdong Li; Sherry D Fleming
Journal:  Clin Immunol       Date:  2012-06-18       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.